Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

EndoGastric Solutions closes $32mm Series C round

Executive Summary

EndoGastric Solutions (formerly EsophyX; medical devices for gastrointestinal disorders) brought in $32mm with its Series C private financing led by Chicago Growth Partners. Other first-time backer Oakwood Medical Investors was joined by returning shareholders MPM Capital, Advanced Technology Ventures, and Foundation Medical Partners. The company will use the funding to continue Phase II trials of its lead product EsophyX for GERD and to develop additional candidates for obesity.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies